Isopropyl Alcohol Inhalation for Cancer-Related Nausea
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial explores whether inhaling isopropyl alcohol can reduce nausea in people with cancer. Participants will inhale either isopropyl alcohol or a placebo to determine which is more effective at easing nausea. Those with cancer who frequently experience moderate to severe nausea might be suitable for this study. Participants must be willing to try inhaling isopropyl alcohol and must not have used certain nausea medications or been exposed to isopropyl alcohol recently. As a Phase 2 trial, this research focuses on measuring the treatment's effectiveness in an initial, smaller group, offering participants a chance to contribute to important findings.
Will I have to stop taking my current medications?
The trial information does not specify if you need to stop taking your current medications. However, you cannot have received anti-nausea medications (anti-emetics) in the last 30 minutes before participating.
Is there any evidence suggesting that this trial's treatments are likely to be safe?
Research has shown that inhaling isopropyl alcohol can quickly reduce nausea. In some studies, participants who inhaled it felt better faster than those who took standard nausea medication. However, strong evidence remains limited, and further research is needed.
Regarding safety, past patients have generally tolerated inhaling isopropyl alcohol well, with no major reports of serious side effects. Some individuals might experience minor nose irritation, though this is uncommon. As this trial is in an early stage, researchers are still gathering more safety information.12345Why do researchers think this study treatment might be promising for cancer-related nausea?
Most treatments for cancer-related nausea involve medications like antiemetics, which work by blocking certain neurotransmitters to reduce nausea and vomiting. However, isopropyl alcohol is unique because it uses a completely different mechanism: inhalation therapy. When inhaled, isopropyl alcohol provides rapid relief by stimulating the olfactory system, which may help distract the brain from nausea signals. This method could offer a quicker and more direct way to manage nausea, making it an exciting alternative for researchers and patients alike.
What evidence suggests that isopropyl alcohol inhalation could be effective for cancer-related nausea?
Research has shown that inhaling isopropyl alcohol can effectively reduce nausea. In this trial, participants in one arm will receive isopropyl alcohol via nasal inhalation. For instance, one study found that patients who inhaled isopropyl alcohol felt less nauseous just 10 minutes later compared to those who inhaled a placebo, a substance with no active ingredients. Another study showed that patients using isopropyl alcohol experienced a greater reduction in nausea than those taking common nausea medications like ondansetron. Although evidence remains limited, these findings suggest that inhaling isopropyl alcohol could be a promising way to manage nausea, especially for cancer patients.12346
Who Is on the Research Team?
Yvonne J. Heung
Principal Investigator
M.D. Anderson Cancer Center
Are You a Good Fit for This Trial?
This trial is for cancer patients experiencing nausea who are seeing a supportive care team. They must be feeling anxious but not delirious, have not used anti-nausea drugs or been exposed to isopropyl alcohol in the last half-hour, and can't have an allergy to isopropyl alcohol.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive either isopropyl alcohol or placebo via nasal inhalation
Follow-up
Participants are monitored for changes in nausea levels post-intervention
What Are the Treatments Tested in This Trial?
Interventions
- Isopropyl Alcohol
- Placebo
Find a Clinic Near You
Who Is Running the Clinical Trial?
M.D. Anderson Cancer Center
Lead Sponsor
National Cancer Institute (NCI)
Collaborator